S. 606 · 118th Congress · Health
Protecting Americans from Dangerous Opioids Act
- IntroducedMar 1, 2023 Done
- CommitteeDied Jan 3, 2025 Stopped here
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill requires the Food and Drug Administration (FDA) to revoke approval for an opioid drug for every new opioid drug approved. (Opioids are drugs with effects similar to opium, such as certain pain medications.) In determining the drug for which to revoke approval, the FDA must prioritize revoking approval for drugs that are not abuse deterrent and consider the public health impact of drugs on the market.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 1, 2023
Who lobbies on it
No lobbying filing on file names S. 606.
Organizations that named S. 606 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
2 actions · newest first- Mar 1, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Mar 1, 2023Introduced in Senate